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OBJECTIVES: To evaluate doctors’ adherence to Malaysian Clinical Practice Guide-
lines on management of hypertension (CPG 2008) in patients with cardiovascular
disease, and factors associated with guidelines adherence and hypertension
control. METHODS: This was a cross sectional study conducted at outpatient car-
diology clinic of Penang Hospital. A total of 13 doctors practicing in the clinic were
enrolled in the study. Prescriptions written by each doctor to 25 established hyper-
tensive patients with cardiovascular disease (total 325) were noted on visit 1 along
with patients’ demographic and clinical data. Implicit review of patients’ medical
record was conducted to find acceptable rationale for nonadherence to guidelines.
The prescriptions written were categorized either as adherent or non-adherent to
CPG (2008). Two hundred sixty of the enrolled 320 patients (20 out of 25 patients
enrolled per doctor) were followed for another one visit. Blood pressure readings
noted on visit 2 were related to prescriptions written on visit 1. SPSS 16 was used for
data analysis. RESULTS: One hundred ninety-one (73.5%) patients received guide-
lines compliant pharmacotherapy. CPG compliance had statistically significant
weak negative association with left ventricular hypertrophy (LVH) ( -0.241,
P0.01), and diabetes ( -0.228, P0.01). One hundred fifty-four (59.2 %) patients
were on goal BP. Hypertension control had statistically significant weak positive
association with guidelines adherence (0.175, P0.01), and Angiotensin con-
verting enzyme inhibitors (0.195, P0.01), while weak negative association with
diabetes mellitus (-0.148, P0.017), left ventricular hypertrophy (LVH) (-
0.153, P0.017) and monotherapy (-0.168, P0.01). CONCLUSIONS: Adherence
to guidelines resulted in better hypertension control. Overall prescribing practices
were in fair compliance with guidelines but room for further improvement is still
present. Doctors’ poor adherence to guidelines in patients with diabetes mellitus
and LVH needs further probing and focus in future.
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OBJECTIVES: To evaluate impact of guidelines adherence and factors associated
with hypertension control METHODS: This was a cross sectional study conducted
at Penang Hospital. Twenty-six doctors; 13 from cardiology, 5 from nephrology and
4 from hypertension and diabetic clinics each were enrolled in the study. Prescrip-
tions written by each doctor to 25 established hypertensive patients (total of 650)
were noted on visit 1 along with patients’ demographic and clinical data. Implicit
review of patients’ medical record was conducted to find acceptable rationale for
non adherence to guidelines. The prescriptions written were categorized either as
compliant or non-compliant to Malaysian Clinical Practice Guidelines on manage-
ment of hypertension (CPG 2008). Five hundred and twenty of the enrolled 650
patients (20 out of 25 patients enrolled per doctor) were followed for another one
visit. BP readings noted on visit 2 were related to the prescriptions written on visit
1. SPSS 16 was used for data analysis. RESULTS: Three hundred forty-nine (67.1%)
patients received guidelines compliant pharmacotherapy. Two hundred sixty-five
(51%) patients were on goal BP on visit 2. Hypertension control had statistically
significant weak positive association with CPG adherence (0.14, P0.01), greater
number of antihypertensive drugs (Effect size 0.11, P0.01), cardiovascular dis-
ease (0.127, P0.01) and management of hypertension at cardiology clinic
(0.13, P0.01), while moderate positive association with Angiotensin converting
enzyme inhibitors (0.20, P0.01). Statistically significant weak negative associ-
ation was observed between hypertension control and diabetes mellitus ( -0.17,
P0.01), renal disease ( -0.17, P 0.01), and management of hypertension at
nephrology ( -0.10, P0.02) and diabetic clinics ( -0.14, P0.01).
CONCLUSIONS: Guidelines adherent pharmacotherapy resulted in better hyper-
tension control. Suboptimal BP control in patients with diabetes mellitus, renal
disease and treated at nephrology and diabetic clinics needs focus and further
probing.
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OBJECTIVES: To conduct cost-effectiveness analysis of bosentan and sildenafil
compared with standard therapy (ST, i.e. calcium channel blockers and warfarin) in
treatment of primary pulmonary arterial hypertension (PAH) in Russian
Federation.METHODS:We undertook cost-effectiveness analysis of bosentan (62.5
mg bid during first 4 weeks and 125 mg bid further) and sildenafil (25 mg tid) and
estimated incremental cost-effectiveness ratios (ICER) for each drug vs ST. A cohort
of 20 patients with PAH, functional class (FC) III was simulated in a model. The
patients either received bosentanST, or sildenafilST, or ST only. The number of
patients whose health state improves by one FC was considered a criterion of
efficacy. Costs of hospitalization, standard therapy medications, and investiga-
tional drugs were calculated in the model. Data on clinical efficacy of bosentan,
sildenafil, and ST were extracted from clinical trials. Patient’s treatment scheme
considered in the model was based on the results of peer interview. RESULTS: In
our model treatment with bosentan was the most effective: 9 of 20 patients versus
6 and 2 of 20 patients who had improved by one FC with bosentan, sildenafil and ST,
respectively. Also, the highest overall costs were in the bosentan group: 1,163,948
USD per 20 patients per year. Overall costs in case of sildenafil and standard ther-
apy were 724,520 and 57,969 USD per group per year, respectively. However, com-
parison of bosentan with ST yielded lower ICER than comparison of sildenafil with
ST: 157,997 and 166,638 USD per one patient with improvement by one FC, respec-
tively. Trend in the results remained the same with bosentan price up to 4400 USD
per pack in one-way sensitivity analysis. CONCLUSIONS: The results of this study
suggest that treatment of FC III PAH with bosentan is more preferable than treat-
ment with sildenafil.
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OBJECTIVES: The objective of this study was to compare, by means of an indirect
treatment comparison (ITC), the efficacy and safety of a bivalirudin-based antico-
agulation strategy to heparin monotherapy, in patients with ST-elevation myocar-
dial infarction (STEMI) intended for primary percutaneous coronary intervention
(PPCI). METHODS: A systematic literature review was performed using Embase,
Medline, Medline In-Progress, and the Cochrane Library to identify randomised
controlled trials (RCTs) to build a network of bivalirudin and heparin monotherapy
strategies in STEMI patients using a common reference strategy (heparin with
glycoprotein IIb/IIIa inhibitor (heparinGPI)). Identified data were analysed using
fixed and random effects Bayesian ITC. A base-case analysis was constructed from
intention-to-treat populations in the RCTs. Outcomes (mortality, stroke, MI, isch-
aemic target vessel revascularisation (I-TVR), major adverse cardiovascular events,
TIMI major and minor bleeding) were evaluated at 30-days and 1 year. RESULTS:
Eight RCTs were identified for inclusion in the ITC. At 30-days the bivalirudin-based
strategy was expected to result in fewer deaths (odds ratio [OR]:0.55; credible in-
terval [CrL]:0.32,0.95) compared to a heparin monotherapy, which was sustained at
1-year (OR:0.50; CrL:0.31, 0.79). Other outcomes [stroke (OR:0.88; CrL:0.37, 2.13); MI
(OR:0.79; CrL:0.40, 1.55); I-TVR (OR:0.75; CrL:0.38, 1.46); TIMI-major (OR:0.85; CrL:
0.47, 1.52) and TIMI-minor (OR:0.70; CrL:0.41, 1.18) bleeding] also tended favourably
towards bivalirudin. Consistent with the HORIZONS-AMI trial, when compared to a
heparinGPI-based strategy, a bivalirudin-based strategy resulted in fewer deaths
(30-days: OR:0.65; CrL:0.43, 1.00 and 1 year: OR:0.70; CrL:0.49, 0.97) and post-proce-
dural bleeding events (30-day TIMI-Major: OR:0.59; CrL:0.42, 0.83 and TIMI-minor:
OR:0.61; CrL:0.42, 0.87)), with comparable ischaemic protection. Scenario analyses
of RCT in/exclusion did not influence base-case findings. CONCLUSIONS: For
STEMI patients intended for PPCI, a bivalirudin-based strategy is expected to result
in fewer deaths at 30-days and 1-year, compared to using heparin monotherapy.
Other ischaemic and bleeding outcomes also tended towards improvement with
bivalirudin.
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OBJECTIVES: To evaluate prescription of guidelines recommended Angiotensin
converting enzyme inhibitors (ACE inhibitors) to established diabetic hypertensive
patients, and factors associated with prescription of ACE inhibitors and hyperten-
sion control. METHODS: This was a cross sectional study conducted at Penang
hospital. Prescriptions written to enrolled 250 established diabetic hypertensive
patients were noted on visit 1 along with demographic and clinical data. Implicit
review of the patients’ medical record was conducted to find acceptable rationale
for non prescription of ACE inhibitors. The enrolled patients were followed for
another one visit and their blood pressure (BP) readings noted on visit 2 were
related to prescriptions written on visit 1. Data was analyzed by SPSS 16. RESULTS:
Two hundred twenty five (86%) patients had multiple comorbidities. The most
prevalent comorbidity was cardiovascular disease (55.6%). Two hundred sixteen
patients (86.4%) were on polytherapy. ACE inhibitors were the most commonly
prescribed antihypertensive agents, prescribed to 158 (63.2%) patients followed by
Beta blockers prescribed to 154 (61.6%) patients. Ninety-two (36.8%) patients were
not on ACE inhibitors, among whom only 8 (8.6%) had contraindications to its use,
and 12 (13%) had diabetic nephropathy and were on guidelines recommended
Angiotensin receptor blockers. Chronic kidney disease had statistically significant
weak negative association with prescription of ACE inhibitors (-0.13, P0.03).
One hundred nine (43.6%) patients were on goal BP on visit 2. Hypertension control
had statistically significant moderate positive association with the use of ACE in-
hibitors (0.26, P0.01), and weak positive association with use of Aldosterone
antagonists (0.13, P0.04), polytherapy (0.17, P0.01), cardiovascular disease
(0.13, P0.03) and male gender (0.13, P0.03). CONCLUSIONS: Despite of
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guidelines recommendations and positive effect of ACE inhibitors on hypertension
control, the use of ACE inhibitors in hypertensive patients suffering from diabetes
mellitus was suboptimal at Penang Hospital.
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OBJECTIVES: Diabetes increases cardiovascular (CV)/renal risk and thus also in-
creases the importance of optimal control of blood pressure (BP), which is generally
poor among hypertensive patients with diabetes. Poor adherence to antihyperten-
sives is common. Electronic monitoring has shown that treatment lapses among
hypertensives frequently exceed the duration of action of most antihypertensives,
allowing the BP to rise, and reducing these drugs’ real-world effectiveness by in-
creasing CV risk. Use of long-acting antihypertensives may improve BP control
among subjects who, like most, miss doses occasionally. Aliskiren, a direct renin
inhibitor, has been shown in the general hypertensive population to suppress BP
well beyond its 24-hour dosing interval. Its BP-lowering effect is almost uninflu-
enced by a single missed dose, and remains strong after treatment interruptions of
a week (longer than almost all dosing errors). This study examines the duration of
action of aliskiren among hypertensive patients with diabetes. METHODS: BP data
from one to 28 days post-withdrawal, from diabetic subjects in six clinical trials,
were modeled to estimate the extent to which use of aliskiren will ameliorate the
effects of imperfect adherence among diabetic subjects, compared to other
antihypertensives. RESULTS: Thirty-four diabetic subjects had their BP measured
24 hours after treatment withdrawal (48 hours after the last dose). The mean (95%
CI) increase in systolic BP from pre-withdrawal baseline was 0.8 (-3.1 to 4.7)
mmHg. Seventy-three diabetic subjects had their BP measured either six or seven
days after withdrawal. The mean (95% CI) increase in systolic BP from the pre-
withdrawal baseline was 3.4 (0.8 to 6.1) mmHg. CONCLUSIONS:Among diabetics,
as in the general hypertensive population, aliskiren retains much of its effect for a
week after stopping treatment. Its duration of action in diabetic subjects covers the
majority of dosing errors. This may confer advantages over other treatments.
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OBJECTIVES: The objective was to evaluate the clinical efficacy of bisoprolol com-
pared to atenolol in reducing the in-clinic and ambulatory blood pressure in pa-
tients with mild to moderate hypertension.METHODS: Studies were retrieved from
Embase, Pubmed, and Cochrane databases using relevant search strategies. Ran-
domised controlled trials which compared bisoprolol with atenolol were included
according to pre-specified inclusion/exclusion criteria. The outcomes of interest
were reduction in in-clinic systolic/diastolic blood pressure, 24-hour ambulatory
BP (ABP), and reduction in heart rate. Two reviewers independently extracted data
from the included studies. Data was meta-analysed using RevMan (v5). RESULTS:
Of the 1056 studies identified, 11 studies met the inclusion criteria. In total, 624
patients were randomised to bisoprolol, and 683 were randomised to atenolol.
Seven of the included studies were double-blind, three were single-blind and one
was open-label study. The Jadad score of eight studies was 3 and were of high
quality. The study duration of included studies ranged from 8-weeks to 52-weeks.
Results of meta-analysis showed a significantly better reduction of clinical systolic
BP with bisoprolol compared to atenolol (WMD: 3.07 (1.79, 4.35, p0.00001). The
reduction in clinical diastolic BP was significantly better with bisoprolol compared
to atenolol (2.68 (1.88, 3.48, p0.00001). The systolic ABP was significantly reduced
with bisoprolol compared to atenolol (p0.001). The reduction in diastolic ABP was
more with bisoprolol but was not significantly better. A significantly better reduc-
tion in heart rate was achieved with bisoprolol compared to atenolol (1.81 (0.97,
2.65, p0.0001).CONCLUSIONS:This review has included the evidence to date with
regards to reduction of clinical and ambulatory blood pressure with bisoprolol
compared to atenolol. This review concludes that bisoprolol is significantly better
than atenolol in effectively reducing the in-clinic BP, ambulatory BP and heart rate
in patients with mild to moderate essential hypertension.
PCV22
GEOGRAPHIC VARIATION TRENDS IN CRITICAL LIMB ISCHEMIA PREVALENCE
IN THE UNITED STATES
Baser O1, Wang L2
1STATinMED Research/The University of Michigan, Ann Arbor, MI, USA, 2STATinMED Research,
Dallas, TX, USA
OBJECTIVES: To examine the geographic variation trends in the annual prevalence
of critical limb ischemia (CLI) in the US elderly population. METHODS: Using na-
tional medical claims data from 2006 through 2008, all patients who were aged 65
years or older and diagnosed with CLI were identified. The direct standardization
method was used to assess year, age, gender, race and diabetes-adjusted preva-
lence of CLI. The change in prevalence of CLI over the 3 years was assessed and the
variation in the prevalence of CLI was tested by state. RESULTS: Geographic vari-
ation in the prevalence of CLI was obtained for patients over the age of 65 when
adjusted by age, gender, race and diabetes status. Although approximately con-
stant prevalence of CLI was reported in Utah (less than 0.15%) and Maryland
(greater than 0.30%), a progressively increasing prevalence of CLI was observed in
Montana (2006: 0.149%; 2007: 0.163.%; 2008: 0.277%) and Delaware (2006: 0.245%;
2007:0.247%; 2008: 0.330%) while progressively decreasing prevalence of CLI was
observed in Arkansas, Colorado, Georgia, Ohio, Virginia, West Virginia, and Wash-
ington. The total trend over 3 years followed the pattern of higher rates in eastern
states and lower rates in western states. CONCLUSIONS: The spatial distribution of
CLI prevalence is uneven and strongly suggests a geographic variation of CLI risk
areas. Targeted prevention and treatment could help gain better control of CLI in
the United States.
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OBJECTIVES: To use a novel linkage database to describe prescribing patterns in
patients discharged from hospital with acute coronary syndrome (ACS) over a pe-
riod of changing national guidelines. METHODS: Unique identifiers were used to
link patients in a hospital registry (Myocardial Ischaemia National Audit Project),
with longitudinal primary care data (General Practice Research Database). This
retrospective observational study examined post-discharge prescribing patterns
for unstable angina (UA), non-ST elevation myocardial infarction (NSTEMI) and ST
elevation MI (STEMI). The population comprised patients 40 years, hospitalised
for ACS from 2003-2009, discharged home, with 3 months follow-up. Patients
were followed from discharge until death, or censoring. A patient was classified as
discontinued if they had no further prescription within the duration of a prescrip-
tion plus a grace period of 90 days. RESULTS: Of the 7,888 linked patients with at
least 3 months of follow-up, 865 had a discharge diagnosis of UA, 4108 NSTEMI and
2915 STEMI. Overall 412(48%) UA, 2820(69%) NSTEMI and 1830(63%) STEMI patients
were treated with clopidogrel in primary care within 3 months of discharge. The
proportion of UA patients treated remained relatively stable over the study period
(2003:47%, 2009:38%), in contrast prescribing increased in NSTEMI (2003:41%, 2009:
78%) and STEMI patients (2003:24%, 2009:87%). Statin use was high in all three
groups (734(85%) UA, 3609(88%) NSTEMI, 2784(96%) STEMI) and remained so
throughout the study period. The median time until discontinuation of medicine
was 12 months for clopidogrel and24 months for statin across all three ACS types.
Patterns of discontinuation remained constant across all study years.
CONCLUSIONS: The proportion of patients with STEMI and NSTEMI treated with
clopidogrel increased from 2003 to 2009, in line with national guideline recommen-
dations. However there was no evidence that clinicians differentiated length of
therapy by type of ACS.
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OBJECTIVES: The aim of the study was to analyze use of ACE inhibitors in Serbia
compared with Montenegro in year 2009. METHODS: Data about use of ACE inhib-
itors in Serbia and in Montenegro in 2009 taken from Republic Institute for Health
Insurance from Serbia and from Health Service Fund of Montenegero. RESULTS:
Use of ACE inhibitors in Serbia in 2009 was 179,26 DDD/1000 inh/day and in Mon-
tenegro was 83,32 DDD/1000 inh/day. In Serbia 5.977.289,00€has been spent for ACE
inhibitors and in Montenegro 2.488.464,95€ in the same year. In Serbia on the first
place is enalapril with 78,32 DDD/1000 inh/day or 44,43%, on the second place
fosinopril with 20,09 DDD/1000 inh/day or 11,40%, while on the third place is
ramipril with 19,11 DDD/1000 inh/day or 10,84% of total drug utilization in this
subgroup. Amount spent on enalapril was 1.717.416,00€ or 28,73%, on fosinopril
1.116.972,00€ or 18,69%, and on ramipril 470.937,00€ or 7,88% of total finances spent
on this subgroup C09 in year 2009. In Montenegro on the first place are lisinopril
and hydrochlorothiazide with 19,62 DDD/1000 inh/day or 23,55%, on the second
place are fosinopril and hydrochlorothiazide with 12,77 DDD/1000 inh/day or
15,33%, while on the third place is fosinopril with 11,92 DDD/1000 inh/day or 14,31%
of total drug utilization inside this subgroup. Money spent on lisinopril and hydro-
chlorothiazide are 425.547,30€ or 17,10%, on fosinopril and hydrochlorothiazide
762.333,74€ or 30,63%, and on fosinopril 533.307,43€ or 21,43% of total finances
spent on this subgroup C09 in the year 2009. CONCLUSIONS: Comparing the con-
sumption of ACE inhibitors in Serbia and Montenegro in the year 2009, it becomes
clear that the combination of ACE inhibitors with diuretics is most frequently used
in Montenegro, while in Serbia the use of this combination is on the the fifth place
in this group of drugs.
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OBJECTIVES: To characterise patients with atrial fibrillation (AF) in a UK secondary
care centre. METHODS: Eligible patients admitted to Llandough Hospital (Cardiff,
UK) as an emergency with AF (ICD10 code: I48X), and discharged between 1/10/2009
A368 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
